scholarly journals XbaI GLUT1 Gene Polymorphism and the Risk of Type 2 Diabetes with Nephropathy

2009 ◽  
Vol 27 (1) ◽  
pp. 29-35 ◽  
Author(s):  
Ioannis Stefanidis ◽  
Kyriakos Kytoudis ◽  
Afroditi A. Papathanasiou ◽  
Dimitrios Zaragotas ◽  
Lambros Melistas ◽  
...  
Keyword(s):  
Diabetic Nephropathy ◽  
Glucose Transporter ◽  
Severe Form ◽  
Altered Expression ◽  
Healthy Control ◽  
Study Population ◽  
Glucose Transporter Glut1 ◽  
Glut1 Gene

Altered expression of the facilitated glucose transporter GLUT1 affects pathways implicated in the pathogenesis of diabetic nephropathy. There is indication that variation of GLUT1 gene (SLC2A1) contributes to development of microangiopathy in diabetes mellitus type 2 (DM) patients. A genetic association study involving Caucasians was carried out to investigate the role of XbαI polymorphism in the GLUT1 gene in diabetic nephropathy (DN). Study population (n= 240) consisted of 148 unrelated patients with DM (92 cases with diabetic nephropathy (DN)), and of 92 matched healthy control subjects. Diabetic nephropathy was defined as persistent albuminuria (> 300 mg/24 h) and/or renal failure, in the absence of non-diabetes induced renal disease. The analysis showed that the risk of developing DM and DN in XbaI(−) carriers, when healthy individuals were considered as controls, was two-fold: odds ratio (OR) 2.08 [95% confidence interval (1.14–3.79)]. However, there was no evidence of association between XbaI(−) and DN when patients with DM and without DN were considered as controls: OR = 1.12 (0.55–2.26). Thus, the GLUT1 XbaI(−) allele is associated with DM, and possibly with a more severe form of the disease that can lead to development of DN.

Polymorphisms of the glucose transporter (GLUT1) gene are associated with diabetic nephropathy

2001 ◽  
Vol 59 (3) ◽  
pp. 985-989 ◽  
Author(s):  
Andrea D. Hodgkinson ◽  
Beverley A. Millward ◽  
Andrew G. Demaine
Keyword(s):  
Diabetic Nephropathy ◽  
Glucose Transporter ◽  
Glucose Transporter Glut1 ◽  
Transporter Glut1 ◽  
Glut1 Gene

scholarly journals Role of GLUT1 gene in susceptibility to diabetic nephropathy in type 2 diabetes

2001 ◽  
Vol 59 (2) ◽  
pp. 631-636 ◽  
Author(s):  
Wladyslaw Grzeszczak ◽  
Dariusz K. Moczulski ◽  
Marcin Zychma ◽  
Ewa Zukowska-Szczechowska ◽  
Wanda Trautsolt ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Diabetic Nephropathy ◽  
Glut1 Gene

scholarly journals An Obesity-RelatedFTOVariant and the Risk of Preeclampsia in a Finnish Study Population

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Miira Klemetti ◽  
Leena M. Hiltunen ◽  
Sanna Heino ◽  
Seppo Heinonen ◽  
Eero Kajantie ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Early Onset ◽  
Elevated Blood ◽  
Study Population ◽  
Normotensive Pregnancy ◽  
Finnish Study ◽  
Risk Of Preeclampsia

Previous studies have demonstrated a common variant of the obesity and fat mass-relatedFTOgene, rs9939609, to be associated with obesity, type 2 diabetes, and elevated blood pressure. We investigated whether theFTOSNP rs9939609 is associated with the risk of preeclampsia (PE) in a Finnish study population. 485 women with prior PE and 449 women who had given birth after a normotensive pregnancy were genotyped (TaqMan) for the SNP rs9939609. The prevalences of genotypes AA, AT, and TT were 15%, 53%, and 32%, respectively, among the PE cases, and 16%, 47%, and 37%, respectively, among the controls (P=0.199). We found no evidence of an association between theFTOSNP rs9939609 and PE. However, our cases were dominated by severe, early-onset PE. Thus, we are unable to exclude an association with the milder, later-onset form of the disease in which the role of maternal metabolic predisposition could be more significant.Erratum to “An Obesity-RelatedFTOVariant and the Risk of Preeclampsia in a Finnish Study Population”

Role of omentin 1 and IL-6 in type 2 diabetes mellitus patients with diabetic nephropathy

2018 ◽  
Vol 12 (1) ◽  
pp. 23-26 ◽  
Author(s):  
Gandhipuram Periyasamy Senthilkumar ◽  
Melepallappil Sabeenakumari Anithalekshmi ◽  
Md. Yasir ◽  
Sreejith Parameswaran ◽  
Rajaa muthu Packirisamy ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Diabetic Nephropathy

scholarly journals Elabela levels in patients with type 2 diabetes: can it be a marker for diabetic nephropathy?

2020 ◽  
Vol 20 (2) ◽  
pp. 833-840
Author(s):  
Erhan Onalan ◽  
Yusuf Doğan ◽  
Ebru Onalan ◽  
Nevzat Gozel ◽  
Ilay Buran ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Diabetic Nephropathy ◽  
High Serum ◽  
Control Group ◽  
Diabetic Patients ◽  
Healthy Individuals ◽  
Urine Albumin ◽  
Healthy Control ◽  
Group 2

Backround: Elabela (ELA) is a hormone that is secreted at high levels in the kidneys of a healthy adult. This study aims to investigate whether serum ELA levels of patients with Type 2 Diabetes vary with the severity of renal damage. Methods: Our study included 50 healthy control subjects and 100 diabetic patients, who were categorized into groups based on urine albumin/creatinine ratios (ACR). Patients included in the study were assigned to four groups: Group 1 (healthy control), Group 2 (ACR<29mg/g), Group 3 (ACR=30-299 mg/g), and Group 4 (ACR>300 mg/g normal or high serum creatinine). Physical examination findings, demographic characteristics of the study group were recorded, and serum ELA levels and other laboratory parameters were assessed using appropriate methods. Results: The results of the study indicated that ELA levels determined in healthy individuals gradually decreased through stages of normal albuminuria, microalbuminuria, and macroalbuminuria. Moreover, ELA had a significant negative corre- lation with LDL-C (r=-0.201, p=0.014), glucose (r=-0.437, P<0.001), retinopathy (r=-0.222, P=0.006), serum BUN (r=- 0.161, P=0.049), and a positive correlation with eGFR (r=0.250, P=0.002). Conclusions: The fact that ELA levels are higher in healthy individuals compared to diabetic patients without microalbu- minuria, and higher in diabetic patients without microalbuminuria compared to patients with advanced albuminuria and kidney damage, suggests that the ELA level can be an important clinical prognostic variable and even a promising agent for the treatment of diabetic nephropathy patients. Keywords: Elabela, diabetes, diabetic kidney disease, albuminuria.

scholarly journals SEVELAMER CARBONATE MODULATES THE NLRP3 AND NLRP6 INFLAMMASOME EXPRESSION IN PATIENTS WITH DIABETIC NEPHROPATHY

2021 ◽  
Vol 80 (2) ◽  
pp. 125-132
Author(s):  
Grațiela Grădișteanu Pîrcălăbioru ◽  
Mariana-Carmen Chifiriuc ◽  
Roxana Adriana Stoica
Keyword(s):  
Diabetic Nephropathy ◽  
Nlrp3 Inflammasome ◽  
Treatment Plan ◽  
Innate Immune ◽  
Pentraxin 3 ◽  
Quantitative Real Time Pcr ◽  
Blood Samples ◽  
Sevelamer Carbonate

Interaction of microorganisms with the host innate immune system is a crucial factor that could modify diabetes and its associated complications. Recent reports have elucidated the role of NLRP3 inflammasome in diabetes, but to our knowledge there is no data regarding the role of other inflammasomes in diabetes-induced inflammation. To investigate this, blood samples were collected from type 2 diabetes (T2DM) patients with nephropathy as well as from healthy volunteers. After red blood cell lysis, RNA was isolated from all collected blood samples. The expression of NLRP 6, NLRP3, ASC, PRO-IL1Β, and PRO-IL18 was assessed by quantitative Real Time PCR (qRT-PCR). Patients with diabetic nephropathy showed higher NLRP3 inflammasome expression compared to healthy controls whereas no significant differences were observed in case of NLRP6 inflammasome. In addition, Pentraxin 3 expression was elevated in patients with diabetic nephropathy. A detailed analysis of the patient’s clinical data revealed the fact that subjects receiving sevelamer carbonate in their treatment plan harboured low expression of Pentraxin 3 (PTX3) and NLRP3 associated genes.

Sign in / Sign up

Export Citation Format

Share Document